A new trading day began on Friday, with Travere Therapeutics Inc (NASDAQ: TVTX) stock price down -4.49% from the previous day of trading, before settling in for the closing price of $18.94. TVTX’s price has ranged from $5.12 to $25.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 13.83% over the past five years. Meanwhile, its annual earnings per share averaged 70.49%. With a float of $87.38 million, this company’s outstanding shares have now reached $87.45 million.
Let’s look at the performance matrix of the company that is accounted for 385 employees. In terms of profitability, gross margin is 92.24%, operating margin of -138.0%, and the pretax margin is -137.45%.
Travere Therapeutics Inc (TVTX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Travere Therapeutics Inc is 1.53%, while institutional ownership is 109.33%. The most recent insider transaction that took place on Feb 12 ’25, was worth 122,356. In this transaction SENIOR VICE PRESIDENT, R&D of this company sold 5,200 shares at a rate of $23.53, taking the stock ownership to the 98,519 shares. Before that another transaction happened on Feb 12 ’25, when Company’s SVP, GC & CORPORATE SECRETARY sold 8,000 for $23.53, making the entire transaction worth $188,240. This insider now owns 89,482 shares in total.
Travere Therapeutics Inc (TVTX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 70.49% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Here are Travere Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.10, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach 0.84 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Travere Therapeutics Inc (NASDAQ: TVTX) saw its 5-day average volume 1.56 million, a negative change from its year-to-date volume of 1.65 million. As of the previous 9 days, the stock’s Stochastic %D was 7.61%. Additionally, its Average True Range was 1.25.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 21.05%, which indicates a significant increase from 0.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.83% in the past 14 days, which was lower than the 54.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.08, while its 200-day Moving Average is $14.51. Nevertheless, the first resistance level for the watch stands at $18.95 in the near term. At $19.82, the stock is likely to face the second major resistance level. The third major resistance level sits at $20.27. If the price goes on to break the first support level at $17.63, it is likely to go to the next support level at $17.18. The third support level lies at $16.31 if the price breaches the second support level.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
With a market capitalization of 1.61 billion, the company has a total of 88,740K Shares Outstanding. Currently, annual sales are 233,180 K while annual income is -321,550 K. The company’s previous quarter sales were 74,790 K while its latest quarter income was -60,260 K.
